ASH 2022 | The efficacy of pooled fecal allogeneic microbiotherapy for refractory gastrointestinal acute GvHD

Florent Malard • 21 Nov 2022

ASH 2022

Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, gives an update on a study evaluating the efficacy of the pooled allogeneic microbiotherapy MaaT013 in patients with steroid-refractory (SR) gastrointestinal (GI) acute graft-versus-host disease (aGvHD). The study found that MaaT013 led to a high GI-overall response rate (ORR), especially in patients previously exposed to ruxolitinib. Dr Malard expects to further confirm these results in an ongoing Phase III study (NCT04769895) in ruxolitinib-refractory patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Therakos/Mallinckrodt: Honoraria; Sanofi: Honoraria; Astellas: Honoraria; JAZZ pharmaceuticals: Honoraria; Biocodex: Honoraria; Janssen: Honoraria; Takeda: Honoraria; Novartis: Honoraria; Gilead: Honoraria; Celgene-BMS: Honoraria.